Laura Stoppel - Jun 10, 2024 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: Director
Signature: /s/ Derek Meisner, Attorney-in-Fact
Stock symbol: ABOS
Transactions as of: Jun 10, 2024
Transactions value $: $0
Form type: 4
Date filed: 6/10/2024, 04:51 PM
Previous filing: Jun 7, 2023
Next filing: Jul 18, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Stock Option (right to buy)	Award	$0	+25K		$0.00	25K	Jun 10, 2024	Common Stock	25K	$2.62	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares subject to the option will vest on the earlier of June 10, 2025 or the 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date.
F2	Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), R.A. Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.

Content

The shares subject to the option will vest on the earlier of June 10, 2025 or the 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through each such vesting date.

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option for the benefit of the R.A. Capital Healthcare Fund, L.P. (the "Fund"), R.A. Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund, Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.